NRP-2945 is under clinical development by CuroNZ and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NRP-2945’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NRP-2945 (NNZ-4945) is under development for the treatment of multiple sclerosis (MS), absence epilepsy, amyotrophic lateral sclerosis (ALS), epileptic encephalopathy, motor neuron diseases Lennox-Gastaut Syndrome (refractory epilepsy), peripheral neuropathy, Rett syndrome, Angelman syndrome, and retinal ischemia. The drug candidate is an 11-mer peptidomimetic that has been chemically modified to enhance stability. The drug candidate is based on Neural Regeneration Peptides Technology. It is administered through subcutaneous route and formulated as solution. It was also under development for the treatment of brain hypoxia and spinal cord injury.
For a complete picture of NRP-2945’s drug-specific PTSR and LoA scores, buy the report here.